At the Annual ASCO meeting in June 2012 [55], a small recent retrospective study evaluated pre-treatment tumor specimens for biomarkers such as HSP90 and HSP70 expression and other client proteins (using immunohistochemical staining) that can predict response to HSP90 inhibitors. Here, HSP90AA1 is linked to neoplasm.